Journal ArticleDOI
Novel therapeutic strategies for treatment of visceral leishmaniasis
Keerti Jain,Narendra Kumar Jain +1 more
Reads0
Chats0
TLDR
This review explores the different facets of novel therapeutic strategies for treatment of visceral leishmaniasis with a purpose to summarize all the possible treatment tactics, which will help scientists working in this arena to implement their research in a systematic manner.About:
This article is published in Drug Discovery Today.The article was published on 2013-12-01. It has received 74 citations till now. The article focuses on the topics: Visceral leishmaniasis & Leishmaniasis.read more
Citations
More filters
Journal ArticleDOI
Advances in Development of New Treatment for Leishmaniasis.
Juliana Perrone Bezerra de Menezes,Carlos Eduardo Sampaio Guedes,Antonio Luis de Oliveira Almeida Petersen,Deborah Bittencourt Mothé Fraga,Patrícia Sampaio Tavares Veras +4 more
TL;DR: How high-throughput analysis is helping the scientific community to identify novel targets for chemotherapeutic interventions and how this helped to identify and assess the potential of new identified targets is discussed.
Journal ArticleDOI
Trends of Gold Nanoparticle-based Drug Delivery System in Cancer Therapy
TL;DR: The limitations and applications of gold nanoparticles in surface modification, targeting strategy, and safety considerations are discussed.
Journal ArticleDOI
Vaccines for visceral leishmaniasis: A review.
Keerti Jain,N. K. Jain +1 more
TL;DR: Visceral leishmaniasis is one of the most severely neglected tropical diseases recognized by the World Health Organization and few vaccines including Leishmune®, Leishtec, and CaniLeish® have been licensed for canine visceral leish maniasis.
Journal ArticleDOI
New approaches from nanomedicine for treating leishmaniasis.
TL;DR: Some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis are presented and further efforts will still be necessary for this therapy to have greater clinical applicability in humans.
Journal ArticleDOI
Drug delivery to macrophages: Challenges and opportunities.
Yihua Pei,Yoon Yeo +1 more
TL;DR: This review provides an overview of representative carriers and various approaches to address challenges in drug delivery to macrophages such as biodistribution, cellular uptake, intracellular trafficking, and drug release.
References
More filters
Journal ArticleDOI
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Jorge Alvar,Pilar Aparicio,Abraham Aseffa,Margriet den Boer,Carmen Cañavate,Jean-Pierre Dedet,Luigi Gradoni,Rachel ter Horst,Rogelio López-Vélez,Javier Moreno +9 more
TL;DR: Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic.
Journal ArticleDOI
Leishmaniasis in Sudan. 3. Visceral leishmaniasis
E.E. Zijlstra,Ahmed M. Elhassan +1 more
TL;DR: Evaluation of diagnostic methods showed that parasitological diagnosis should still be the mainstay in diagnosis, with sensitivities for lymph node, bone marrow and spleen aspirates of 58%, 70% and 96%, respectively, and simple, cheap serological tests are needed.
Journal ArticleDOI
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Shyam Sundar,Prabhat K. Sinha,Madhukar Rai,Deepak Kumar Verma,Kumar Nawin,Shanawwaj Alam,Jaya Chakravarty,Michel Vaillant,Neena Verma,Krishna Pandey,Poonam Kumari,Chandra Shekhar Lal,Rakesh Kumar Arora,Bhawna Sharma,Sally Ellis,Nathalie Strub-Wourgaft,Manica Balasegaram,Piero Olliaro,Pradeep Das,Farrokh Modabber +19 more
TL;DR: Combination treatments for visceral leishmaniasis are efficacious and safe, and decrease the duration of therapy, thereby encouraging adherence and reducing emergence of drug-resistant parasites.
Journal ArticleDOI
Combination therapy for visceral leishmaniasis
Johan van Griensven,Manica Balasegaram,Filip Meheus,Jorge Alvar,Lutgarde Lynen,Marleen Boelaert +5 more
TL;DR: The evidence and potential for combination therapy, and the criteria for the choice of drugs in such regimens, are reviewed, suggesting that combination therapy is more cost-effective and reduces indirect costs for patients.
Journal ArticleDOI
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
TL;DR: Liposomal amphotericin B remains a first-line option for empirical therapy in patients with febrile neutropenia and in those with disseminated histoplasmosis, and is an option for the treatment of AIDS-associated cryptococcal meningitis, and for invasive Candida spp.